Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,106 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Follow-Up Questions
Regeneron Pharmaceuticals Inc (REGN)'in P/E oranı nedir?
Regeneron Pharmaceuticals Inc 'in P/E oranı 13.4131 'dir
Regeneron Pharmaceuticals Inc 'in CEO'su kimdir?
Dr. Leonard Schleifer 1988 'den beri şirketle birlikte olan Regeneron Pharmaceuticals Inc 'in Co-Chairman of the Board 'ıdır.
REGN hissesinin fiyat performansı nasıl?
REGN 'in mevcut fiyatı $629.11 'dir, son işlem günde 0.17% increased etti.
Regeneron Pharmaceuticals Inc için ana iş temaları veya sektörler nelerdir?
Regeneron Pharmaceuticals Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 30 analist Regeneron Pharmaceuticals Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 10 güçlü al, 17 al, 7 tut, 1 sat ve 10 güçlü sat içermektedir
